Comparing the current results to its competitors, Ac Immune Sa reported Revenue decrease in the 4 quarter 2025 year on year by -86.92 %, faster than the overall decrease of Ac Immune Sa's competitors by -20.99 %, recorded in the same quarter.
Ac Immune Sa's Comment on Competition and Industry Peers
The company faces risks related to protecting its intellectual property and trade secrets, including potential breaches by third parties such as contract research organizations (CROs), academic partners, funding organizations, and licensing or collaboration partners. Maintaining confidentiality can be challenging, and competitors or third parties may lawfully obtain or independently develop the company's trade secrets, which could weaken its competitive position. Additionally, foreign laws may offer less protection for proprietary rights compared to U.S. laws, complicating efforts to safeguard intellectual property internationally.
December 10, 2024
Headwinds and Progress: Analyzing AC Immune s Phase 1b/2 Trial Results Amidst Revenue Struggles In a landscape where biopharmaceutical companies continually strive to innovate, AC Immune SA recently reported interim safety data from their Phase 1b/2 ABATE trial of ACI-24.060, a potential therapeutic intervention for individuals with Down syndrome. This investigational treatment aims to address cognitive deficits associated with the condition, marking a significant step forward in the quest for effective therapies in what is often an under-researched area.The ABATE trial has garnered attention not only for its scientific merit but also for the implications it holds for the wider research community working t...
January 22, 2024
AC Immune, a Swiss-based biopharmaceutical company, has announced that it will regain the global rights to two of its key drug candidates, Crenezumab and Semorinemab. This decision comes as part of the company s strategy to strengthen and expand its portfolio in the field of neurodegenerative diseases, particularly Alzheimer s disease.Crenezumab is a monoclonal antibody that targets the beta-amyloid protein, which is believed to play a major role in the development and progression of Alzheimer s disease. AC Immune, in collaboration with Genentech, initially developed Crenezumab and conducted a Phase 2 clinical trial to assess its safety and efficacy. Despite the trial s inconclusive results, subsequent analy...
Acadia Pharmaceuticals Inc's business model centers around the research, development, and commercialization of innovative medicines for diseases related to the central nervous system. They collaborate with a network of partners and employ a combination of in-house research and licensing agreements to discover and develop drug candidates. Their primary revenue stream comes from the sales of approved products, with a focus on providing effective therapeutic options for patients with unmet medical needs.
Amylyx Pharmaceuticals Inc's business model revolves around researching, developing, and commercializing potential therapies for neurodegenerative diseases. They aim to identify promising drug candidates, conduct preclinical and clinical trials, and ultimately gain regulatory approval to market and sell their products. By focusing on innovative treatments, Amylyx Pharmaceuticals Inc aims to address unmet medical needs in the field of neurodegenerative disorders.
Alterity Therapeutics Limited's business model focuses on the development of innovative therapies to treat neurodegenerative diseases, with a special emphasis on Parkinson's disease and Alzheimer's disease.
Clene Inc's business model focuses on developing and commercializing novel nanocatalysts to enhance energy storage systems and improve the efficiency and performance of clean energy technologies.
Crinetics Pharmaceuticals Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. They primarily generate revenue through the sale of their developed drugs and potential partnerships with other pharmaceutical companies.
Sources:
Ac Immune Sa’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Ac Immune Sa versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
